Global Soft Tissue Sarcomas Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Soft Tissue Sarcomas Treatment Market Analysis

The soft tissue sarcomas treatment market is expected to grow significantly due to increasing incidences of soft tissue sarcomas (STS) globally, advancements in treatment options, and a better understanding of genetic mutations driving these cancers. Soft tissue sarcomas are rare, accounting for about 1% of all adult cancers, with higher incidence rates seen in countries with advanced healthcare systems. Treatment strategies have evolved with technological advancements in precision medicine, targeted therapies, and immunotherapy. For instance, drugs such as Larotrectinib and Vitrakvi have shown promising results for patients with sarcoma harboring specific genetic mutations, such as TRK fusion proteins. Moreover, CAR-T cell therapies are being explored for aggressive cases, with ongoing trials to assess their effectiveness in STS treatment. Radiotherapy, chemotherapy, and surgical resection remain core treatment options, while genomic profiling and personalized treatments are becoming increasingly popular. In addition, the growth of healthcare infrastructure and the rise in clinical trials are driving market demand. Government initiatives, alongside private sector investments, are accelerating innovation, creating a robust pipeline of therapies aimed at improving survival rates for soft tissue sarcoma patients.

Soft Tissue Sarcomas Treatment Market Size

The global Soft Tissue Sarcomas Treatment market size was valued at USD 1.52 billion in 2024 and is projected to reach USD 2.51 billion by 2032, with a CAGR of 6.49% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Soft Tissue Sarcomas Treatment Market Trends

“Increasing Targeted Therapies and Immunotherapy”

The Soft Tissue Sarcomas Treatment Market is witnessing a significant trend toward targeted therapies and immunotherapy as advanced treatment options. With an increasing understanding of the genetic makeup of soft tissue sarcomas, treatments such as Larotrectinib (Vitrakvi) have become pivotal in targeting specific mutations, such as TRK fusion proteins, found in sarcomas. This targeted approach allows for more precise and effective treatments with fewer side effects compared to traditional therapies. In addition, the development of CAR-T cell therapies is showing promise in treating advanced or resistant forms of soft tissue sarcomas, offering hope to patients with few remaining options. For instance, the Kite Pharma's KTE-X19 is currently being evaluated in clinical trials for soft tissue sarcomas. As more personalized treatments emerge, the demand for genomic profiling and precision medicine in sarcoma care is expected to increase, transforming how these cancers are treated. This trend is significantly contributing to the market growth, supported by expanding clinical trials and investments.

Report Scope and Soft Tissue Sarcomas Treatment Market Segmentation         

Soft Tissue Sarcomas Treatment Market Definition

Soft Tissue Sarcomas Treatment refers to the medical approaches and therapies used to manage and treat soft tissue sarcomas, a group of rare cancers that develop in the soft tissues of the body, such as muscles, fat, blood vessels, nerves, and connective tissues. Treatment options typically include surgical resection, where the tumor is surgically removed, radiotherapy to target cancer cells, and chemotherapy to kill or shrink tumors.

Soft Tissue Sarcomas Treatment Market Dynamics

Drivers

• Rising Prevalence of Soft Tissue Sarcomas (STS)

The rising incidence of soft tissue sarcomas (STS) is a significant driver of the treatment market, as the number of diagnosed cases continues to grow globally. According to the American Cancer Society, approximately 13,000 new cases of soft tissue sarcomas are diagnosed annually in the U.S. alone, with increasing rates observed due to better diagnostic methods and heightened awareness. Advances in imaging techniques and genetic profiling have contributed to earlier and more accurate detection, leading to a higher number of diagnosed cases, especially in regions with advanced healthcare infrastructure. This growing patient pool is creating an urgent demand for effective treatment options, including surgical resection, chemotherapy, and innovative therapies such as targeted treatments and immunotherapy. The increasing prevalence of STS further drives market growth as healthcare providers seek cutting-edge solutions to improve survival rates and treatment outcomes for patients. This trend is expected to propel the soft tissue sarcoma treatment market forward.

•  Expanding Clinical Trials Focused on Soft Tissue Sarcoma

Expanding clinical trials focused on soft tissue sarcoma (STS) treatments are significantly driving the demand for newer, more effective therapies. Ongoing trials are investigating the use of genomic profiling, which enables the identification of specific genetic mutations in sarcoma tumors, allowing for the development of targeted therapies tailored to individual patients. For instance, trials involving Larotrectinib (Vitrakvi) have shown promise in treating TRK fusion-positive sarcomas, a subtype of STS with specific genetic mutations. These advancements are improving treatment efficacy and creating a broader market for personalized treatments, which are gaining traction in the oncology field. The increasing number of clinical trials, backed by both public and private sector investments, is accelerating the discovery of new therapies, making it a key market driver. As more therapies move into clinical phases and show promise in treating various subtypes of STS, the demand for these innovative treatments continues to rise, further fueling market growth.

Opportunities

• Increasing Advancements in Targeted Therapies and Immunotherapy

Advancements in targeted therapies and immunotherapy are revolutionizing the treatment landscape for soft tissue sarcomas (STS), creating significant market opportunities. The development of treatments such as Larotrectinib (Vitrakvi) has proven highly effective for patients with TRK fusion-positive sarcomas, demonstrating the potential of targeting specific genetic mutations in tumors. Similarly, CAR-T cell therapies are gaining momentum, offering a personalized approach by using genetically modified T-cells to target and attack cancer cells. Kite Pharma's KTE-X19 is currently undergoing clinical trials for its use in treating aggressive forms of STS. These therapies represent a shift from traditional chemotherapy, providing more precise, effective, and less toxic options for patients. As these advanced treatments continue to show promise in clinical settings, the demand for genomic profiling and personalized treatment regimens is expected to grow, creating ample market opportunities. These innovations are improving patient outcomes but are also positioning targeted therapies and immunotherapy as key drivers of future market growth in the STS treatment sector.

•  Increasing Government and Private Sector Investments

Government and private sector investments are playing a crucial role in advancing sarcoma therapies, creating significant market opportunities. Increased funding from government agencies, such as the National Cancer Institute (NCI) in the U.S., and private entities such as pharmaceutical companies and biotech firms, is driving research and development of novel treatments for soft tissue sarcomas. For instance, the Cancer Moonshot initiative, backed by the U.S. government, has provided substantial funding for cancer research, including projects focused on targeted therapies and immunotherapy for sarcomas. In addition, private companies such as Bristol-Myers Squibb and Pfizer are investing heavily in developing next-generation therapies, including CAR-T cell therapies and genetic profiling technologies. These investments are fueling breakthroughs that enhance treatment outcomes and patient survival rates, fostering a growing demand for innovative therapies. As R&D in sarcoma treatment continues to accelerate, the influx of both public and private funding presents a significant market opportunity, driving the development of advanced treatments and expanding access to life-saving therapies for sarcoma patients.

Restraints/Challenges

• High Treatment Costs

The high treatment costs for soft tissue sarcomas (STS) present a significant barrier to both patient access and market adoption, particularly in low- and middle-income countries. Treatment for STS often involves complex surgical procedures, extended chemotherapy regimens, and advanced radiation therapies, all of which come with substantial costs. For instance, in countries such as Brazil and India, where healthcare budgets are limited, patients may struggle to afford the necessary treatments, and hospitals may not have the resources to provide advanced therapies. Furthermore, newer treatment options, such as targeted therapies or immunotherapies, are often priced at a premium, making them inaccessible to many patients. These high costs exacerbate disparities in care, with individuals in wealthier regions or those with better insurance coverage able to access cutting-edge treatments, while those in less developed regions may face delayed or inadequate care. This affordability issue represents a major market challenge, as pharmaceutical companies must find ways to reduce costs or develop more accessible treatment models without compromising efficacy. Addressing these cost-related barriers is essential to ensuring equitable access to care and expanding the reach of effective STS therapies.

• Resistance to Chemotherapy

Resistance to chemotherapy is a major challenge in the treatment of soft tissue sarcomas (STS), as many subtypes of the disease show limited responsiveness to traditional chemotherapeutic agents. This resistance significantly reduces the effectiveness of existing treatments, particularly for patients with recurrent or metastatic STS. For instance, patients with undifferentiated pleomorphic sarcoma (UPS) or liposarcoma, common subtypes of STS, often show poor responses to chemotherapy, which hampers their overall prognosis. The lack of effective adjuvant therapies that can complement chemotherapy further complicates treatment, as patients are left with fewer viable options when their tumors become resistant. This ongoing issue contributes to poor survival rates and makes it difficult to achieve long-term remission, posing a significant hurdle in the management of the disease. From a market perspective, the limited success of chemotherapy-based regimens increases the demand for innovative therapies, such as targeted treatments or immunotherapies, creating an opportunity for pharmaceutical companies and presenting challenges in terms of developing and bringing these new therapies to market. The ongoing need for more effective treatment options highlights the importance of research into overcoming chemotherapy resistance in STS.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Soft Tissue Sarcomas Treatment Market Scope

The market is segmented on the basis of disease type, local recurrence rate, treatment type, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Angiosarcoma
• Dermatofibrosarcoma
• Epithelioid Sarcoma
• Others

Local Recurrence Rate

• Children
• Adults

Treatment Type

• Surgery
• Radiotherapy
• Chemotherapy
• Targeted Drug Therapy

End User

• Hospitals
• Specialty Clinics
• Others

Soft Tissue Sarcomas Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, disease type, local recurrence rate, treatment type, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to dominate the market during the forecast period, driven by a rise in research and development activities, technological advancements, and strong support from both government and private sectors, which have significantly boosted healthcare spending. In addition, the growing awareness of febrile seizures, coupled with improvements in well-established healthcare infrastructure, plays a crucial role in driving market growth in the region.

Asia-Pacific is projected to be the fastest-growing market during the forecast period, driven by increasing financial support from both government and private sectors. In addition, advancements in healthcare technologies and significant biotechnological innovations in countries such as Japan, South Korea, China, and others are key contributors to new research and development initiatives.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Soft Tissue Sarcomas Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Soft Tissue Sarcomas Treatment Market Leaders Operating in the Market Are:

• Sanofi (France)
• Cardinal Health (U.S.)
• Merck KGaA (Germany)
• Pfizer (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• GSK plc (U.K.)
• Celgene Corporations (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• BioHorizons (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Atrium Medical Technologies (U.S.)
• Smith+Nephew (U.K.)
• Boston Scientific Corporation (U.S.)
• AbbVie Inc (U.S.)
• Dentsply (U.S.)
• Novavax (U.S.)
• Cook (U.S.)
• LifeCell International Pvt. Ltd. (India)
• Lilly (U.S.)

Latest Developments in Soft Tissue Sarcomas Treatment Market

• In May 2023, Bayer announced that Larotrectinib sulfate is currently undergoing phase II clinical trials, designed for the treatment of sarcoma with solid tumors in both adults and children
• In June 2023, CancerVAX, Inc., the developer of a revolutionary universal cancer vaccine that utilizes the immune system to combat cancer, launched a $10 million financing round. The funds raised through an SEC-approved Reg A+ sale will help advance its groundbreaking cancer treatments. The company is collaborating with UCLA to develop targeted therapies for Ewing sarcoma, an aggressive cancer affecting young individuals' bones and soft tissues
• In March 2022, Phio Pharmaceuticals Corp., a biotechnology firm specializing in immuno-oncology drugs based on its self-delivering RNAi therapeutic platform, announced a partnership with AgonOx, Inc. The collaboration aims to develop cancer drugs by combining AgonOx’s tumor-infiltrating T-cell technology with Phio’s RNAi platform
• In January 2021, Pfizer announced that the European Commission had approved Vitrakvi (larotrectinib) for the treatment of advanced soft tissue sarcoma. Vitrakvi is a targeted therapy for patients whose malignancies contain a specific genetic mutation
• In June 2021, Johnson & Johnson revealed that its drug JNJ-4528 had been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma. Though not specifically for soft tissue sarcoma, JNJ-4528 is a CAR-T cell therapy being developed for various malignancies, including certain types of sarcoma

SKU-59913